Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bacterial Infections and Mycoses

  Free Subscription


Articles published in J Antimicrob Chemother

Retrieve available abstracts of 139 articles:
HTML format
Text format



Single Articles


    June 2017
  1. DI SANTE L, Morroni G, Brenciani A, Vignaroli C, et al
    pHTbeta-promoted mobilization of non-conjugative resistance plasmids from Enterococcus faecium to Enterococcus faecalis.
    J Antimicrob Chemother. 2017 Jun 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. BUIL JB, Rijs AJMM, Meis JF, Birch M, et al
    In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
    J Antimicrob Chemother. 2017 Jun 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. HURST SF, Berkow EL, Stevenson KL, Litvintseva AP, et al
    Isolation of azole-resistant Aspergillus fumigatus from the environment in the south-eastern USA.
    J Antimicrob Chemother. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. KAUSHIK A, Ammerman NC, Tasneen R, Story-Roller E, et al
    In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  5. HAMMERUM AM, Baig S, Kamel Y, Roer L, et al
    Emergence of vanA Enterococcus faecium in Denmark, 2005-15.
    J Antimicrob Chemother. 2017 May 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. MAITRE T, Petitjean G, Chauffour A, Bernard C, et al
    Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?
    J Antimicrob Chemother. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. YIM J, Smith JR, Singh NB, Rice S, et al
    Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs).
    J Antimicrob Chemother. 2017 May 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. BEN YAAKOV D, Shadkchan Y, Albert N, Kontoyiannis DP, et al
    The quinoline bromoquinol exhibits broad-spectrum antifungal activity and induces oxidative stress and apoptosis in Aspergillus fumigatus.
    J Antimicrob Chemother. 2017 May 5. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2017
  9. ZIMENKOV DV, Nosova EY, Kulagina EV, Antonova OV, et al
    Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
    J Antimicrob Chemother. 2017 Apr 6. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  10. SAN-JUAN R, Fernandez-Ruiz M, Gasch O, Camoez M, et al
    High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus.
    J Antimicrob Chemother. 2017 Mar 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. GURUMURTHY M, Verma R, Naftalin CM, Hee KH, et al
    Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial.
    J Antimicrob Chemother. 2017 Mar 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. HAWKINS PA, Law CS, Metcalf BJ, Chochua S, et al
    Cross-resistance to lincosamides, streptogramins A and pleuromutilins in Streptococcus agalactiae isolates from the USA.
    J Antimicrob Chemother. 2017 Mar 13. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. JAGANATH D, Schaaf HS, Donald PR
    Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.
    J Antimicrob Chemother. 2017 Mar 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. GRONTHAL T, Eklund M, Thomson K, Piiparinen H, et al
    Antimicrobial resistance in Staphylococcus pseudintermedius and the molecular epidemiology of methicillin-resistant S. pseudintermedius in small animals in Finland.
    J Antimicrob Chemother. 2017 Mar 8. doi: 10.1093.
    PubMed     Text format    


  15. DE LASTOURS V, Maugy E, Mathy V, Chau F, et al
    Ecological impact of ciprofloxacin on commensal enterococci in healthy volunteers.
    J Antimicrob Chemother. 2017 Mar 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. BLANCHARD AC, Fortin E, Laferriere C, Goyer I, et al
    Comparative effectiveness of linezolid versus vancomycin as definitive antibiotic therapy for heterogeneously resistant vancomycin-intermediate coagulase-negative staphylococcal central-line-associated bloodstream infections in a neonatal intensive ca
    J Antimicrob Chemother. 2017 Mar 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. LEDOUX MP, Toussaint E, Denis J, Herbrecht R, et al
    New pharmacological opportunities for the treatment of invasive mould diseases.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  18. BASSETTI M, Bouza E
    Invasive mould infections in the ICU setting: complexities and solutions.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  19. MERCIER T, Maertens J
    Clinical considerations in the early treatment of invasive mould infections and disease.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  20. LAMOTH F, Calandra T
    Early diagnosis of invasive mould infections and disease.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  21. STOTT KE, Hope WW
    Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  22. LASS-FLORL C, Cuenca-Estrella M
    Changes in the epidemiological landscape of invasive mould infections and disease.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


    February 2017
  23. MOUGARI F, Loiseau J, Veziris N, Bernard C, et al
    Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria.
    J Antimicrob Chemother. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. CAVANAUGH JS, Jou R, Wu MH, Dalton T, et al
    Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
    J Antimicrob Chemother. 2017 Feb 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. RUDRAMURTHY SM, Chakrabarti A, Paul RA, Sood P, et al
    Candida auris candidaemia in Indian ICUs: analysis of risk factors.
    J Antimicrob Chemother. 2017 Feb 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. PERICAS JM, Garcia-de-la-Maria C, Brunet M, Armero Y, et al
    Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.
    J Antimicrob Chemother. 2017 Feb 14. doi: 10.1093.
    PubMed     Text format    


  27. MARCOS-ZAMBRANO LJ, Gomez-Perosanz M, Escribano P, Bouza E, et al
    The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.
    J Antimicrob Chemother. 2017 Feb 8. doi: 10.1093.
    PubMed     Text format    


  28. BOIKOV DA, Locke JB, James KD, Bartizal K, et al
    In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis.
    J Antimicrob Chemother. 2017 Feb 3. doi: 10.1093.
    PubMed     Text format    


    January 2017
  29. WERTH BJ
    Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.
    J Antimicrob Chemother. 2017 Jan 31. doi: 10.1093.
    PubMed     Text format    


  30. LEDDA A, Price JR, Cole K, Llewelyn MJ, et al
    Re-emergence of methicillin susceptibility in a resistant lineage of Staphylococcus aureus.
    J Antimicrob Chemother. 2017 Jan 20. pii: dkw570. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. LARSEN J, Andersen PS, Winstel V, Peschel A, et al
    Staphylococcus aureus CC395 harbours a novel composite staphylococcal cassette chromosome mec element.
    J Antimicrob Chemother. 2017 Jan 14. pii: dkw544. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. GOTHAM D, Fortunak J, Pozniak A, Khoo S, et al
    Estimated generic prices for novel treatments for drug-resistant tuberculosis.
    J Antimicrob Chemother. 2017 Jan 10. pii: dkw522. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. HOMBACH M, Weissert C, Senn MM, Zbinden R, et al
    Comparison of phenotypic methods for the detection of penicillinase in Staphylococcus aureus and proposal of a practical diagnostic approach.
    J Antimicrob Chemother. 2017 Jan 8. pii: dkw521. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. XISTO MI, Caramalho RD, Rocha DA, Ferreira-Pereira A, et al
    Pan-azole-resistant Candida tropicalis carrying homozygous erg11 mutations at position K143R: a new emerging superbug?
    J Antimicrob Chemother. 2017 Jan 8. pii: dkw558. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. GRONTHAL T, Eklund M, Thomson K, Piiparinen H, et al
    Antimicrobial resistance in Staphylococcus pseudintermedius and the molecular epidemiology of methicillin-resistant S. pseudintermedius in small animals in Finland.
    J Antimicrob Chemother. 2017 Jan 8. pii: dkw559. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2016
  36. KATRAGKOU A, Williams M, Sternberg S, Pantazatos D, et al
    Micafungin alters the amino acid, nucleic acid and central carbon metabolism of Candida albicans at subinhibitory concentrations: novel insights into mechanisms of action.
    J Antimicrob Chemother. 2016 Dec 30. pii: dkw478. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. ZHU XQ, Wang XM, Li H, Shang YH, et al
    Novel lnu(G) gene conferring resistance to lincomycin by nucleotidylation, located on Tn6260 from Enterococcus faecalis E531.
    J Antimicrob Chemother. 2016 Dec 30. pii: dkw549. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. VAN HAL SJ, Espedido BA, Coombs GW, Howden BP, et al
    Polyclonal emergence of vanA vancomycin-resistant Enterococcus faecium in Australia.
    J Antimicrob Chemother. 2016 Dec 28. pii: dkw539. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. RUPPEN C, Hemphill A, Sendi P
    In vitro activity of gentamicin as an adjunct to penicillin against biofilm group B Streptococcus.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw447. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. ZAPOTOCZNA M, Murray EJ, Hogan S, O'Gara JP, et al
    5-Hydroxyethyl-3-tetradecanoyltetramic acid represents a novel treatment for intravascular catheter infections due to Staphylococcus aureus.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw482. doi: 10.1093.
    PubMed     Text format     Abstract available


  41. BUTIN M, Martins-Simoes P, Pichon B, Leyssene D, et al
    Emergence and dissemination of a linezolid-resistant Staphylococcus capitis clone in Europe.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw516. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. CAVACO LM, Bernal JF, Zankari E, Leon M, et al
    Detection of linezolid resistance due to the optrA gene in Enterococcus faecalis from poultry meat from the American continent (Colombia).
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw490. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. BRITT NS, Patel N, Shireman TI, El Atrouni WI, et al
    Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw453. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. ROBERTSON GT, Scherman MS, Bruhn DF, Liu J, et al
    Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw467. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. YUSTE JR, Berto J, Del Pozo JL, Leiva J, et al
    Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw484. doi: 10.1093.
    PubMed     Text format    


  46. TANIGUCHI R, Kimura K, Miyazaki A, Banno H, et al
    High rate of slowly-killed-by-ampicillin phenotype among group B streptococci with reduced penicillin susceptibility.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw500. doi: 10.1093.
    PubMed     Text format    


    November 2016
  47. SWEENEY D, Stoneburner A, Shinabarger DL, Arhin FF, et al
    Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  48. MAERTENS JA, Blennow O, Duarte RF, Munoz P, et al
    The current management landscape: aspergillosis.
    J Antimicrob Chemother. 2016;71.
    PubMed     Text format     Abstract available


    October 2016
  49. AMMERMAN NC, Swanson RV, Tapley A, Moodley C, et al
    Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  50. CANTON R, Livermore DM, Morosini MI, Diaz-Reganon J, et al
    Etest(R) versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: results from PREMIUM, a European multicentre study.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


    September 2016
  51. TEDIM AP, Ruiz-Garbajosa P, Rodriguez MC, Rodriguez-Banos M, et al
    Long-term clonal dynamics of Enterococcus faecium strains causing bloodstream infections (1995-2015) in Spain.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  52. KUBICEK-SUTHERLAND JZ, Lofton H, Vestergaard M, Hjort K, et al
    Antimicrobial peptide exposure selects for Staphylococcus aureus resistance to human defence peptides.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  53. ARGUDIN MA, Dodemont M, Taguemount M, Roisin S, et al
    In vitro activity of ceftaroline against clinical Staphylococcus aureus isolates collected during a national survey conducted in Belgian hospitals.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  54. HOFFMANN H, Borroni E, Schena E, Nedialkova L, et al
    Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system-authors' response.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  55. MORICI E, Simoni S, Brenciani A, Giovanetti E, et al
    A new mosaic integrative and conjugative element from Streptococcus agalactiae carrying resistance genes for chloramphenicol (catQ) and macrolides [mef(I) and erm(TR)].
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  56. MENDES RE, Castanheira M, Farrell DJ, Flamm RK, et al
    Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  57. BERNARD C, Aubry A, Chauffour A, Brossier F, et al
    In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  58. PINHOLT M, Gumpert H, Bayliss S, Nielsen JB, et al
    Genomic analysis of 495 vancomycin-resistant Enterococcus faecium reveals broad dissemination of a vanA plasmid in more than 19 clones from Copenhagen, Denmark.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  59. FUURSTED K, Stegger M, Hoffmann S, Lambertsen L, et al
    Description and characterization of a penicillin-resistant Streptococcus dysgalactiae subsp. equisimilis clone isolated from blood in three epidemiologically linked patients.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


    August 2016
  60. WILSON LK, Coombs GW, Christiansen K, Grubb WB, et al
    Characterization of a novel staphylococcal cassette chromosome composite island from community-associated MRSA isolated in aged care facilities in Western Australia.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  61. VALENTIN A, Canton E, Peman J, Fernandez-Rivero ME, et al
    In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  62. FREITAS AR, Tedim AP, Francia MV, Jensen LB, et al
    Multilevel population genetic analysis of vanA and vanB Enterococcus faecium causing nosocomial outbreaks in 27 countries (1986-2012).
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  63. CHONG GM, van der Beek MT, von dem Borne PA, Boelens J, et al
    PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay(R) in 201 patients with haematological disease suspected for invasive aspergillosis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  64. IMKAMP F, Keller PM, Bottger EC
    Comment on: Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  65. CARTER GP, Buultjens AH, Ballard SA, Baines SL, et al
    Emergence of endemic MLST non-typeable vancomycin-resistant Enterococcus faecium.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  66. LAHIRI SD, Alm RA
    Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  67. VERWEIJ PE, Lestrade PP, Melchers WJ, Meis JF, et al
    Azole resistance surveillance in Aspergillus fumigatus: beneficial or biased?
    J Antimicrob Chemother. 2016;71:2079-82.
    PubMed     Text format     Abstract available


  68. ALANIO A, Denis B, Hamane S, Raffoux E, et al
    New therapeutic strategies for invasive aspergillosis in the era of azole resistance: how should the prevalence of azole resistance be defined?
    J Antimicrob Chemother. 2016;71:2075-8.
    PubMed     Text format     Abstract available


    July 2016
  69. CHIOTOS K, Vendetti N, Zaoutis TE, Baddley J, et al
    Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  70. SIOPI M, Siafakas N, Vourli S, Mouton JW, et al
    Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  71. THORNLEY T, Marshall G, Howard P, Wilson AP, et al
    A feasibility service evaluation of screening and treatment of group A streptococcal pharyngitis in community pharmacies.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  72. TSAO S, Weber S, Cameron C, Nehme D, et al
    Positive regulation of the Candida albicans multidrug efflux pump Cdr1p function by phosphorylation of its N-terminal extension.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  73. BASAS J, Morer A, Ratia C, Martin MT, et al
    Efficacy of anidulafungin in the treatment of experimental Candida parapsilosis catheter infection using an antifungal-lock technique.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


    June 2016
  74. SINEL C, Cosquer T, Auzou M, Goux D, et al
    Sequential steps of daptomycin resistance in Enterococcus faecium and reversion to hypersusceptibility through IS-mediated inactivation of the liaFSR operon.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  75. CONCEICAO T, de Lencastre H, Aires-de-Sousa M
    Efficacy of octenidine against antibiotic-resistant Staphylococcus aureus epidemic clones.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  76. PFALLER MA, Messer SA, Rhomberg PR, Jones RN, et al
    Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  77. MARTINEZ-JIMENEZ MC, Munoz P, Valerio M, Vena A, et al
    Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  78. EILERTSON B, Maruri F, Blackman A, Guo Y, et al
    A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  79. SABIROVA JS, Xavier BB, Coppens J, Zarkotou O, et al
    Whole-genome typing and characterization of blaVIM19-harbouring ST383 Klebsiella pneumoniae by PFGE, whole-genome mapping and WGS.
    J Antimicrob Chemother. 2016;71:1501-9.
    PubMed     Text format     Abstract available


  80. WIENER-WELL Y, Raveh-Brawer D, Fraenkel-Wandel Y, Yinnon AM, et al
    Mortality due to blaKPC Klebsiella pneumoniae bacteraemia-authors' response.
    J Antimicrob Chemother. 2016;71:1744.
    PubMed     Text format    


  81. GIACOBBE DR, Tumbarello M, Del Bono V, Viscoli C, et al
    Comment on: Mortality due to blaKPC Klebsiella pneumoniae bacteraemia.
    J Antimicrob Chemother. 2016;71:1743-4.
    PubMed     Text format    


  82. HAENNI M, Saras E, Ponsin C, Dahmen S, et al
    High prevalence of international ESBL CTX-M-15-producing Enterobacter cloacae ST114 clone in animals.
    J Antimicrob Chemother. 2016;71:1497-500.
    PubMed     Text format     Abstract available


  83. FERNANDEZ J, Poirel L, Rodicio MR, Nordmann P, et al
    Concomitant and multiclonal dissemination of OXA-48-producing Klebsiella pneumoniae in a Spanish hospital.
    J Antimicrob Chemother. 2016;71:1734-6.
    PubMed     Text format    


    May 2016
  84. PANTEL A, Petrella S, Veziris N, Matrat S, et al
    Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  85. BARCHIESI F, Santinelli A, Biscotti T, Greganti G, et al
    Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  86. NILSEN E, Aasterod M, Hustad PS, Olsen AO, et al
    Mecillinam against genital Chlamydia trachomatis infection: a small-scale proof-of-concept study shows a low cure rate.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  87. LIU P, Xue H, Wu Z, Ma J, et al
    Effect of bla regulators on the susceptible phenotype and phenotypic conversion for oxacillin-susceptible mecA-positive staphylococcal isolates.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  88. VAN PH, Binh PT, Minh NH, Morrissey I, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 in Vietnam.
    J Antimicrob Chemother. 2016;71 Suppl 1:i93-i102.
    PubMed     Text format     Abstract available


  89. TORUMKUNEY D, Gur D, Soyletir G, Gurler N, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2002-09 in Turkey.
    J Antimicrob Chemother. 2016;71 Suppl 1:i85-i91.
    PubMed     Text format     Abstract available


  90. SOYLETIR G, Altinkanat G, Gur D, Altun B, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in Turkey.
    J Antimicrob Chemother. 2016;71 Suppl 1:i71-i83.
    PubMed     Text format     Abstract available


  91. FESHCHENKO Y, Dzyublik A, Pertseva T, Bratus E, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in Ukraine.
    J Antimicrob Chemother. 2016;71 Suppl 1:i63-i69.
    PubMed     Text format     Abstract available


  92. JAMSHEER A, Rafay AM, Daoud Z, Morrissey I, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in the Gulf States.
    J Antimicrob Chemother. 2016;71 Suppl 1:i45-i61.
    PubMed     Text format     Abstract available


  93. HU F, Zhu D, Wang F, Morrissey I, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 and 2013-14 in China.
    J Antimicrob Chemother. 2016;71 Suppl 1:i33-i43.
    PubMed     Text format     Abstract available


  94. TORUMKUNEY D, Chaiwarith R, Reechaipichitkul W, Malatham K, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2012-14 in Thailand, India, South Korea and Singapore.
    J Antimicrob Chemother. 2016;71 Suppl 1:i3-i19.
    PubMed     Text format     Abstract available


  95. KACOU-NDOUBA A, Revathi G, Mwathi P, Seck A, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2011-14 in the Democratic Republic of Congo, Ivory Coast, Republic of Senegal and Kenya.
    J Antimicrob Chemother. 2016;71 Suppl 1:i21-i31.
    PubMed     Text format     Abstract available


  96. ENNE VI, Johnson AP, Perry JD
    Preface.
    J Antimicrob Chemother. 2016;71 Suppl 1:i1.
    PubMed     Text format    


  97. TORNERO E, Morata L, Martinez-Pastor JC, Angulo S, et al
    Importance of selection and duration of antibiotic regimen in prosthetic joint infections treated with debridement and implant retention.
    J Antimicrob Chemother. 2016;71:1395-401.
    PubMed     Text format     Abstract available


  98. REIGADAS E, Alcala L, Valerio M, Marin M, et al
    Toxin B PCR cycle threshold as a predictor of poor outcome of Clostridium difficile infection: a derivation and validation cohort study.
    J Antimicrob Chemother. 2016;71:1380-5.
    PubMed     Text format     Abstract available


  99. VAN DEN ABEELE AM, Vogelaers D, Vanlaere E, Houf K, et al
    Antimicrobial susceptibility testing of Arcobacter butzleri and Arcobacter cryaerophilus strains isolated from Belgian patients.
    J Antimicrob Chemother. 2016;71:1241-4.
    PubMed     Text format     Abstract available


  100. LINKEVICIUS M, Anderssen JM, Sandegren L, Andersson DI, et al
    Fitness of Escherichia coli mutants with reduced susceptibility to tigecycline.
    J Antimicrob Chemother. 2016;71:1307-13.
    PubMed     Text format     Abstract available


  101. FINDLAY J, Hopkins KL, Doumith M, Meunier D, et al
    KPC enzymes in the UK: an analysis of the first 160 cases outside the North-West region.
    J Antimicrob Chemother. 2016;71:1199-206.
    PubMed     Text format     Abstract available


  102. BOWKER KE, Noel AR, Tomaselli S, MacGowan AP, et al
    Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.
    J Antimicrob Chemother. 2016;71:1270-8.
    PubMed     Text format     Abstract available


  103. KUMARASWAMY M, Lin L, Olson J, Sun CF, et al
    Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia.
    J Antimicrob Chemother. 2016;71:1264-9.
    PubMed     Text format     Abstract available


  104. MOORE JH 2ND, van Opstal E, Kolling GL, Shin JH, et al
    Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model.
    J Antimicrob Chemother. 2016;71:1300-6.
    PubMed     Text format     Abstract available


  105. JOST C, Bidet P, Carrere T, Mariani-Kurkdjian P, et al
    Susceptibility of enterohaemorrhagic Escherichia coli to azithromycin in France and analysis of resistance mechanisms.
    J Antimicrob Chemother. 2016;71:1183-7.
    PubMed     Text format     Abstract available


  106. COJUTTI P, Duranti S, Isola M, Baraldo M, et al
    Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?
    J Antimicrob Chemother. 2016;71:1323-9.
    PubMed     Text format     Abstract available


  107. BRASSEUR A, Hites M, Roisin S, Cotton F, et al
    A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study.
    J Antimicrob Chemother. 2016;71:1386-94.
    PubMed     Text format     Abstract available


  108. MUJAL A, Sola J, Hernandez M, Villarino MA, et al
    Safety and effectiveness of outpatient parenteral antimicrobial therapy in older people.
    J Antimicrob Chemother. 2016;71:1402-7.
    PubMed     Text format     Abstract available


  109. GLUPCZYNSKI Y, Evrard S, Ote I, Mertens P, et al
    Evaluation of two new commercial immunochromatographic assays for the rapid detection of OXA-48 and KPC carbapenemases from cultured bacteria.
    J Antimicrob Chemother. 2016;71:1217-22.
    PubMed     Text format     Abstract available


  110. MURATA S, Mushino T, Hosoi H, Kuriyama K, et al
    Extracorporeal antimicrobial elimination enables antimicrobial mixing and affects resident bacteria.
    J Antimicrob Chemother. 2016;71:1430-2.
    PubMed     Text format    


  111. BATHOORN E, Tsioutis C, da Silva Voorham JM, Scoulica EV, et al
    Emergence of pan-resistance in KPC-2 carbapenemase-producing Klebsiella pneumoniae in Crete, Greece: a close call.
    J Antimicrob Chemother. 2016;71:1207-12.
    PubMed     Text format     Abstract available


  112. KOSTYANEV T, Strateva T, Xavier BB, Marteva-Proevska Y, et al
    Detection and characterization of two NDM-1-producing Klebsiella pneumoniae strains from Bulgaria.
    J Antimicrob Chemother. 2016;71:1428-30.
    PubMed     Text format    


  113. DAY MJ, Rodriguez I, van Essen-Zandbergen A, Dierikx C, et al
    Diversity of STs, plasmids and ESBL genes among Escherichia coli from humans, animals and food in Germany, the Netherlands and the UK.
    J Antimicrob Chemother. 2016;71:1178-82.
    PubMed     Text format     Abstract available


  114. KIM JC, Jeon B
    Novel adjuvant strategy to potentiate bacitracin against MDR MRSA.
    J Antimicrob Chemother. 2016;71:1260-3.
    PubMed     Text format     Abstract available


  115. MILLAR MR, Seale J, Turton J, Wilks M, et al
    ESBL-producing Enterobacteriaceae in 24 neonatal units and associated networks in the south of England: no clustering of ESBL-producing Escherichia coli in units or networks.
    J Antimicrob Chemother. 2016;71:1174-7.
    PubMed     Text format     Abstract available


    March 2016
  116. HAMIDIAN M, Hall RM
    The resistance gene complement of D4, a multiply antibiotic-resistant ST25 Acinetobacter baumannii isolate, resides in two genomic islands and a plasmid.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  117. FINCH R
    Professor Francis William O'Grady, 7 November 1925-20 May 2015.
    J Antimicrob Chemother. 2016;71:567-8.
    PubMed     Text format    


  118. KAMESHWAR K, Karahalios A, Janus E, Karunajeewa H, et al
    False economies in home-based parenteral antibiotic treatment: a health-economic case study of management of lower-limb cellulitis in Australia.
    J Antimicrob Chemother. 2016;71:830-5.
    PubMed     Text format     Abstract available


  119. THOMPSON CN, Thieu NT, Vinh PV, Duc AN, et al
    Clinical implications of reduced susceptibility to fluoroquinolones in paediatric Shigella sonnei and Shigella flexneri infections.
    J Antimicrob Chemother. 2016;71:807-15.
    PubMed     Text format     Abstract available


  120. CAMPOS J, Mourao J, Marcal S, Machado J, et al
    Clinical Salmonella Typhimurium ST34 with metal tolerance genes and an IncHI2 plasmid carrying oqxAB-aac(6')-Ib-cr from Europe.
    J Antimicrob Chemother. 2016;71:843-5.
    PubMed     Text format    


  121. KINGSLEY J, Mehra P, Lawrence LE, Henry E, et al
    A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin.
    J Antimicrob Chemother. 2016;71:821-9.
    PubMed     Text format     Abstract available


  122. SAKTIAWATI AM, Sturkenboom MG, Stienstra Y, Subronto YW, et al
    Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.
    J Antimicrob Chemother. 2016;71:703-10.
    PubMed     Text format     Abstract available


  123. RIEU R, Chang C, Collin SM, Fazekas J, et al
    Time to detection in liquid culture of sputum in pulmonary MDR-TB does not predict culture conversion for early discharge.
    J Antimicrob Chemother. 2016;71:803-6.
    PubMed     Text format     Abstract available


  124. VAN DER BIJ AK, Frentz D, Bonten MJ
    Gram-positive cocci in Dutch ICUs with and without selective decontamination of the oropharyngeal and digestive tract: a retrospective database analysis.
    J Antimicrob Chemother. 2016;71:816-20.
    PubMed     Text format     Abstract available


  125. BRUMLEY PE, Malani AN, Kabara JJ, Pisani J, et al
    Effect of an antimicrobial stewardship bundle for patients with Clostridium difficile infection.
    J Antimicrob Chemother. 2016;71:836-40.
    PubMed     Text format     Abstract available


  126. KOMP LINDGREN P, Higgins PG, Seifert H, Cars O, et al
    Prevalence of hypermutators among clinical Acinetobacter baumannii isolates.
    J Antimicrob Chemother. 2016;71:661-5.
    PubMed     Text format     Abstract available


  127. YOON EJ, Goussard S, Nemec A, Lambert T, et al
    Origin in Acinetobacter gyllenbergii and dissemination of aminoglycoside-modifying enzyme AAC(6')-Ih.
    J Antimicrob Chemother. 2016;71:601-6.
    PubMed     Text format     Abstract available


  128. VAN KONINGSBRUGGEN-RIETSCHEL S, Heuer HE, Merkel N, Posselt HG, et al
    Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
    J Antimicrob Chemother. 2016;71:711-7.
    PubMed     Text format     Abstract available


  129. STRUKOVA EN, Portnoy YA, Zinner SH, Firsov AA, et al
    Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
    J Antimicrob Chemother. 2016;71:678-84.
    PubMed     Text format     Abstract available


  130. CORNELY OA, Duarte RF, Haider S, Chandrasekar P, et al
    Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
    J Antimicrob Chemother. 2016;71:718-26.
    PubMed     Text format     Abstract available


  131. FLOREZ-CUADRADO D, Ugarte-Ruiz M, Quesada A, Palomo G, et al
    Description of an erm(B)-carrying Campylobacter coli isolate in Europe.
    J Antimicrob Chemother. 2016;71:841-3.
    PubMed     Text format    


  132. WANG Y, Dong Y, Deng F, Liu D, et al
    Species shift and multidrug resistance of Campylobacter from chicken and swine, China, 2008-14.
    J Antimicrob Chemother. 2016;71:666-9.
    PubMed     Text format     Abstract available


  133. KULLAR R, Sakoulas G, Deresinski S, van Hal SJ, et al
    When sepsis persists: a review of MRSA bacteraemia salvage therapy.
    J Antimicrob Chemother. 2016;71:576-86.
    PubMed     Text format     Abstract available


    January 2016
  134. PFEIFER Y, Hunfeld KP, Borgmann S, Maneg D, et al
    Carbapenem-resistant Acinetobacter baumannii ST78 with OXA-72 carbapenemase and ESBL gene blaCTX-M-115.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  135. PAPAREDDY P, Kasetty G, Kalle M, Bhongir RK, et al
    NLF20: an antimicrobial peptide with therapeutic potential against invasive Pseudomonas aeruginosa infection.
    J Antimicrob Chemother. 2016;71:170-80.
    PubMed     Text format     Abstract available


  136. VAN DUIJKEREN E, Hengeveld P, Zomer TP, Landman F, et al
    Transmission of MRSA between humans and animals on duck and turkey farms.
    J Antimicrob Chemother. 2016;71:58-62.
    PubMed     Text format     Abstract available


  137. GOMEZ P, Lozano C, Camacho MC, Lima-Barbero JF, et al
    Detection of MRSA ST3061-t843-mecC and ST398-t011-mecA in white stork nestlings exposed to human residues.
    J Antimicrob Chemother. 2016;71:53-7.
    PubMed     Text format     Abstract available


    November 2015
  138. BIELICKI JA, Sharland M, Johnson AP, Henderson KL, et al
    Selecting appropriate empirical antibiotic regimens for paediatric bloodstream infections: application of a Bayesian decision model to local and pooled antimicrobial resistance surveillance data.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


    October 2015
  139. KARLOWSKY JA, Biedenbach DJ, Bouchillon SK, Iaconis JP, et al
    In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bacterial Infections and Mycoses is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: